News

October 15, 2018October 15, 2018

#ECTRIMS2018 – Additional Analysis on Ozanimod Demonstrate Its Potential to Treat Relapsing MS

News

Additional analysis of clinical data from Celgene’s investigational agent ozanimod continues to demonstrate its potential to benefit patients with relapsing multiple sclerosis (MS). Findings from the ... Read more

October 15, 2018October 15, 2018

#ECTRIMS2018 – Post-hoc Analyses Support Safety and Efficacy of Mavenclad, Merck Says

News

Substantial data supporting both the effectiveness and safety of Mavenclad (cladribine tablets) is before the U.S. Food and Drug Administration (FDA), and may lead to its ... Read more

October 15, 2018October 15, 2018

#ECTRIMS2018 — As Siponimod Awaits FDA Decision, Mouse Work Helps in Understanding Benefits Seen in SPMS

News

Mouse studies of siponimod — a potential progressive multiple sclerosis (MS) treatment that’s up for approval in the U.S. and EU — were among presentations given by ... Read more

October 15, 2018October 15, 2018

#ECTRIMS2018 – Plasma Neurofilament Light Levels Linked to Treatment Effects in RRMS, Study Finds

News

Levels of proposed biomarker neurofilament light chain (NfL) are associated with therapeutic effects of disease-modifying treatments (DMTs) in relapsing-remitting multiple sclerosis (RRMS) patients, according to a real-world study. ... Read more

October 15, 2018October 15, 2018

#ECTRIMS2018 – Smoking and Vitamin D Deficiency Likely to Worsen CIS Prognosis, Model Suggests

News

Smoking and low levels of vitamin D can worsen prognosis for people with clinically isolated syndrome (CIS), researchers who developed a model for predicting long-term disability ... Read more

October 15, 2018October 15, 2018

#ECTRIMS2018 – Excessive Weight, But Not Vitamin D, Linked with Faster Grey Matter Loss in MS, Study Finds

News

Being overweight is associated with accelerated grey matter volume loss in the brain, a mark of neurodegeneration, in multiple sclerosis (MS) patients, a five-year observational study shows. ... Read more

October 12, 2018October 12, 2018

#ECTRIMS2018: Study Proposes Serum Neurofilament Light Threshold to Identify RRMS Patients at Risk of Worsening

News

Relapsing-remitting multiple sclerosis (RRMS) patients with serum neurofilament light chain (sNfL) levels higher than a proposed threshold have a higher risk of disease activity, and worsened ... Read more

October 12, 2018October 12, 2018

#ECTRIMS2018 — In CIS Patients, Early Lesions in Specific Brain Area Linked to Worse Disability 30 Years Later, Study Shows

News

Lesions in the infratentorial region of the brain at the onset of clinically isolated syndrome (CIS) and lesions in white matter one year after CIS onset are ... Read more

October 12, 2018October 12, 2018

#ECTRIMS2018 – From Sun to Salt: Growing Role of Environment in MS

News

A person’s genes influence the development of multiple sclerosis (MS), but so does the environment — both that in which an MS patient lives, and that ... Read more

October 12, 2018October 12, 2018

#ECTRIMS2018 — Early Relapses and Larger Lesions Increase Risk of Developing SPMS, Study Reports

News

A higher frequency of early relapses, as well as a larger volume of lesions and older age at disease onset, increase the risk of transitioning from ... Read more

October 12, 2018October 12, 2018

#ECTRIMS2018 – MS Patients More Prone to Health Problems Before, After Diagnosis, Study Suggests

News

Patients with multiple sclerosis (MS) are more likely to experience health problems before they receive their formal diagnosis, as well as to experience serious non-MS-related complications ... Read more

October 11, 2018October 11, 2018

#ECTRIMS2018 — Infections, Severe Disability Complications More Likely Causes of Death in MS Patients, Study Shows

News

Infections and complications from severe disability are the greatest contributors to mortality among multiple sclerosis (MS) patients, according to a population-based study in British Columbia, Canada, which ... Read more

October 11, 2018October 11, 2018

#ECTRIMS2018 — MS Patients with Depression or Bipolar Disorder at Higher Risk of Disability Worsening, Study Finds

News

Multiple sclerosis (MS) patients with depression or bipolar disorder may be at higher risk of becoming incapacitated and seeing their disability worsen faster, according to a ... Read more

October 11, 2018October 11, 2018

#ECTRIMS2018 – Brain, Spinal Cord Injuries Affect Processing Speed in MS Patients, Study Reveals

News

Processing speed is associated with the extent of brain and spinal cord injury in patients with multiple sclerosis (MS), according to a new study conducted in ... Read more

October 11, 2018October 11, 2018

#ECTRIMS2018 — Data from 2 EU Trials Shows Effectiveness of Cannabidiol Spray in Treating Spasticity

News

Data from two European trials — a real-life study in Italy, and a long-term Czech trial looking at impact on cognition — supported the efficacy of ... Read more

October 11, 2018October 11, 2018

#ECTRIMS2018 – Rituximab for MS Does Not Increase Cancer Risk Compared to Gilenya and Tysabri, Swedish Study Finds

News

Treatment of multiple sclerosis (MS) patients with rituximab does not increase breast cancer risk in women, and is not associated with a higher risk for malignant ... Read more

October 11, 2018October 11, 2018

#ECTRIMS2018 – Lower Mortality Rate in US, Sweden for MS Patients Treated With Rituximab, Study Reports

News

Treatment of multiple sclerosis (MS) patients with rituximab leads to lower-than-reported mortality rates, according to a large real-world study in the U.S. and Sweden. The findings ... Read more

October 10, 2018October 10, 2018

#ECTRIMS2018 — Vitamin D May Boost Glucocorticosteroid Effectiveness in MS Relapses, Study Suggests

News

Vitamin D may increase the therapeutic benefits of glucocorticosteroids (GCs) for multiple sclerosis (MS) through a protein complex called mTORc1, according to a study in a mouse ... Read more

October 10, 2018October 10, 2018

#ECTRIMS2018 – Switching to Tysabri Leads to Fewer Relapses and Disability than Gilenya, Study in RRMS Patients Finds

News

Patients with relapsing-remitting multiple sclerosis (RRMS) who switch to Tysabri (natalizumab) after relapses on first-line treatment with other medications show greater relapse reduction and less disability ... Read more

October 10, 2018October 10, 2018

#ECTRIMS2018 – DMTs Slow Down Disability Progression in SPMS Patients with Ongoing Relapses, Analysis Shows

News

Treatment with disease-modifying therapies (DMTs) may benefit patients with secondary progressive multiple sclerosis (SPMS) who are actively experiencing relapses, as they can slow the disability’s worsening, ... Read more

October 10, 2018October 10, 2018

#ECTRIMS2018 — Merck KGaA to Present Latest Data on MS Portfolio

News

Merck KGaA will present the latest advances made on several of its therapies aiming to treat multiple sclerosis (MS) at the 34th Congress of the European ... Read more

October 10, 2018October 10, 2018

#ECTRIMS2018 – Researcher Presents Data About Myelocortical MS, a New Disease Subtype

News

A new subtype of multiple sclerosis (MS) — called myelocortical MS (MCMS) — is characterized by cortical neuronal loss, but not by loss of myelin in ... Read more

October 10, 2018October 10, 2018

FDA, EMA Agree to Review Novartis Therapy Siponimod to Treat SPMS

News

Novartis is seeking U.S. and European approval of its investigational oral agent siponimod to treat adults with secondary progressive multiple sclerosis (SPMS). The U.S. Food and Drug ... Read more

October 9, 2018October 9, 2018

Pregnancy Rates Rise Among Women with MS Over Past Decade in US, Study Shows

News

In recent years, pregnancy rates have increased among women with multiple sclerosis (MS) in the United States, according to a retrospective study, but the rate of ... Read more

October 9, 2018October 9, 2018

EMD Serono, ACP Work Jointly to Make MS Clinical Trials More Patient-focused

News

The Accelerated Cure Project (ACP) for Multiple Sclerosis and EMD Serono— a unit of Merck KGaA —  will jointly incorporate the perspectives of U.S. and Canadian multiple sclerosis (MS) ... Read more

October 8, 2018October 8, 2018

National MS Society Awards $12M to 40 Research Projects in US and Elsewhere

News

The National Multiple Sclerosis Society (NMSS) has pledged $12 million to support 40 new, multi-year research projects focused on “stopping MS, restoring lost function, and ending the ... Read more

October 8, 2018October 8, 2018

UVA Scientist Awarded $5.6M by NIH to Further Study Lymph System and Brain Connection

News

Jonathan Kipnis, the researcher who discovered that lymphatic vessels are important mediators of the underlying molecular mechanism of multiple sclerosis (MS), has received the prestigious Director’s ... Read more

October 5, 2018October 11, 2018

#ECTRIMS2018 — Biogen’s MS Treatments Found Safe, Effective in Clinical and Real-world Data

News

Clinical data and real-world results support the long-term efficacy of Biogen’s medications for multiple sclerosis (MS), according to scientific presentations being released by the company. Specifically, ... Read more

October 4, 2018October 11, 2018

#ECTRIMS2018 – Genentech to Present Ocrevus-related MS Studies at Conference

News

Treatment with Ocrevus (ocrelizumab) over five years lessened upper limb disability progression in primary progressive multiple sclerosis (PPMS) patients, reduced relapses and brain disease activity in ... Read more

October 4, 2018October 8, 2018

#ECTRIMS2018 – Emerging MS Treatments, from Cannabinoids to Diet, Among Highlights at Conference

News

Thousands of scientists, doctors, pharmaceutical company executives and others — representing about 100 countries — will meet for three days to discuss and debate the latest ... Read more

October 3, 2018October 3, 2018

Risk of Kidney Deterioration Low in MS Patients, Study Suggests

News

The rate of kidney deterioration as a result of bladder dysfunction due to multiple sclerosis (MS) is low, affecting only 3 percent of the patients, a ... Read more

October 3, 2018October 3, 2018

NMSS Praises Federal Funding of Data Collection for MS, Other Diseases

News

A new U.S. law designed to update and expand data on Americans with multiple sclerosis (MS) and similar illnesses will significantly advance disease research, said the ... Read more

October 2, 2018October 8, 2018

New Genetic Variants Linked to Aggressive or Benign MS Disease Course, Study Shows

News

Genetic variants in the CPXM2, IGSF9B, and NLRP9 genes were found to potentially shape the disease course of multiple sclerosis (MS), and may be used as biomarkers to ... Read more

October 2, 2018October 2, 2018

Lower Fatigue Reported by MS Patients after aHSCT in Canadian Study

News

A small group of multiple sclerosis (MS) patients with aggressive disease, who were treated with hematopoietic stem cell transplant in a clinical trial, reported a drop ... Read more

October 1, 2018October 1, 2018

Cannabidiol-derived Treatment for MS, EHP-101, Enters Phase 1 Safety Study, Emerald Health Says

News

Emerald Health Pharmaceuticals announced that it has begun enrolling healthy volunteers for a Phase 1 clinical trial evaluating the safety and tolerability of EHP-101, a potential cannabidiol treatment for ... Read more

October 1, 2018October 3, 2018

MS Patients Using Rebif Not at Higher Stroke Risk, Even Over Long-term, Study Reports

News

Multiple sclerosis patients using Rebif (interferon beta-1a) are not at an increased risk of a stroke, even if remaining on this therapy for more than two years,  a ... Read more

September 28, 2018September 28, 2018

New Assessment Tool Shows Effect of Social Networks on MS Patient Outcomes

News

A person’s social network can have an effect on their functional disability. This is what researchers discovered when they applied an online assessment tool they developed ... Read more

September 28, 2018October 8, 2018

#ECTRIMS2018 – Ublituximab Markedly Reduces Lesions, Promotes B-cell Depletion, Halts Disability Progression in Phase 2 Trial

News

A 48-week treatment of relapsing multiple sclerosis (MS) with TG Therapeutics’ investigational compound ublituximab led to a marked reduction of brain and spinal cord lesions, massive ... Read more

September 27, 2018October 3, 2018

Smoking May Speed Up MS Progression, Lower Treatment Effectiveness, Study Reports

News

Smoking may increase multiple sclerosis (MS) disease activity, quicken disability progression, and speed the transition from relapsing to secondary progressive MS (SPMS) by as much as ... Read more

September 27, 2018October 2, 2018

Often-overlooked MRI Signal May Aid in Early Diagnosis of MS, Other Brain Conditions, Study Suggests

News

Scientists have found that a usually-overlooked signal from MRI scans indicates brain regions of nerve cell death and may help in the understanding of brain development and ... Read more